ASX Share rice
Thu 13 May 2021 - 01:47:pm (Sydney)

CCE Share Price

CARNEGIE CLEAN ENERGY LIMITEDCCEUtilities

CCE Company Information

Name:

Carnegie Clean Energy Limited

Sector:

Utilities

Industry:

Utilities-Renewable

GIC Industry:

Independent Power and Renewable Electricity Producers

GIC Sub Industry:

Independent Power Producers & Energy Traders

Address:

21 North Mole Drive North Fremantle WA Australia 6159

Phone:

61 8 6168 8400

Chief Exec. Officer:

Mr. Jonathan Fievez BEng (Mecht)

Independent Non Exec. Director & Company Sec.:

Mr. Grant Jonathan Mooney C.A., BBus, CA

Interim CFO & Commercial Mang.:

Ms. Rebecca Cutter

Chief Operating Officer:

Mr. David Kessel

Admin. Mang.:

Ms. Tegan Brookman Dip. Bus Mngt, Cert Iv Bus

Company Overview:

Carnegie Clean Energy Limited develops and commercializes the CETO wave energy technology for converting ocean wave energy into zero-emission electricity worldwide. It also produces and sells clean renewable energy using solar and associated battery systems to the Department of Defense. Carnegie Clean Energy Limited has collaboration agreement with Hewlett Packard Enterprise Company to develop a reinforcement learning based controller for the CETO wave energy technology. The company was formerly known as Carnegie Wave Energy Limited and changed its name to Carnegie Clean Energy Limited in December 2016. Carnegie Clean Energy Limited was incorporated in 1987 and is headquartered in North Fremantle, Australia.

CCE Share Price Information

Shares Issued:

13.08B

Market Capitalisation:

$39.24M

Revenue (TTM):

$11.28K

Earnings per Share:

$-0.035

Operating Margin (TTM):

$-149.62

Return On Assets (TTM):

$-0.05

Return On Equity (TTM):

$-0.11

Quarterly Revenue Growth (YOY):

-0.998

Gross Profit(TTM):

$65.50K

CCE CashFlow Statement

CashFlow Date:

2020-06-30

Investments:

$-664,169

Change To Liabilities:

$-4,997,040

Total Cashflow From Investing Activities:

$-664,169

Net Borrowings:

$-31,277

Net Income:

$-275,522

Total Cash From Operating Activities:

$-1,424,607

Depreciation:

$399.68K

Other Cashflow From Investing Activities:

$-662,480

Change To Account Receivables:

$1.95M

Sale Purchase Of Stock:

$5.53M

Capital Expenditures:

$1.69K

CCE Income Statement

Income Date:

2020-06-30

Income Before Tax:

$-1,812,380

Net Income:

$-275,520

Gross Profit:

$-575,750

Operating Income:

$-1,635,460

Other Operating Expenses:

$-50,371

Interest Expense:

$176.92K

Total Revenue:

$187.67K

Cost Of Revenue:

$763.42K

CCE Balance Sheet

Balance Sheet Date:

2020-06-30

Intangible Assets:

$14.59M

Total Liabilities:

$3.34M

Total Stockholder Equity:

$17.86M

Total Assets:

$21.21M

Common Stock:

$203.22M

Retained Earnings:

$-186,245,965

Other Liabilities:

$51.84K

Other Assets:

$542.26K

Cash:

$3.41M

Total Current Liabilities:

$3.24M

Property - Plant & Equipment:

$2.48M

Net Tangible Assets:

$3.27M

Long-Term Investments:

$12.41K

Total Current Assets:

$3.58M

Net Receivables:

$169.82K

Short-Term Investments:

$17.62M

Accounts Payable:

$210.62K

Short-Term Investments:

$17.62

Non Current Liabilities Total:

$100.44K

CCE Share Price History

CCE News

14 Sep, 2020
First Patient Enrolled in AVITA Therapeutic’s Pivotal Study Evaluating the RECELL System for Repigmentation of Stable Vitiligo
07 Sep, 2020
While AVITA Therapeutics, Inc. (ASX:AVH) shareholders are probably generally happy, the stock hasn't had particularly...
03 Sep, 2020
AVITA Therapeutics to Participate in Upcoming Investor Conferences
28 Aug, 2020
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
26 Aug, 2020
AVITA Therapeutics Provides Company Update and Revised Corporate Presentation
29 Jul, 2020
AVITA Therapeutics, Inc. (NASDAQ: RCEL) (ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that management will present at the Canaccord Genuity 40th Annual Virtual Growth Conference on 12 August 2020 at 8:30 a.m. EDT.
13 Jul, 2020
AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that the Biomedical Advanced Research and Development Authority (BARDA), a part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS), will procure the RECELL® System as part of the HHS mission to build preparedness for public health emergencies.
09 Jul, 2020
AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today preliminary unaudited results for the fourth quarter and full year ended June 30, 2020, together with a company update.
08 Jul, 2020
A look at the shareholders of AVITA Therapeutics, Inc. (ASX:AVH) can tell us which group is most powerful...
02 Jun, 2020
AVITA Medical Limited (ASX: AVH) (NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, today announced that it has submitted an Investigational Device Exemption (IDE) supplement with the U.S. Food and Drug Administration (FDA) for the initiation of a pivotal clinical trial to investigate the RECELL® System for the treatment of vitiligo.
21 May, 2020
AVITA Medical to Participate at the Jefferies Virtual Healthcare Conference
13 May, 2020
AVITA Medical to Participate at Oppenheimer's MedTech Summit